Aligos Therapeutics Appoints Kieron Wesson, PhD, as VP and Head Of CMC To Strengthen Manufacturing Leadership

Aligos Therapeutics, Inc. has named Kieron Wesson, PhD, as its new Vice President and Head of Chemistry Manufacturing Controls (CMC), effective immediately. The clinical-stage biopharmaceutical company, which focuses on developing leading therapies for liver and viral diseases, believes Dr. Wesson’s extensive experience will play a critical role in enhancing its CMC strategies and advancing its therapeutic programs.

“I am thrilled to join Aligos at this important time as we look to begin our Phase 2 study of ALG-000184 in mid-2025. I look forward to contributing my CMC expertise to our mission of improving patient outcomes in liver and viral diseases,” said Kieron Wesson, PhD, Vice President, Head of CMC at Aligos.

Dr. Wesson brings over two decades of pharmaceutical development experience to Aligos. He has previously held key leadership roles in CMC and supply chain operations at Kezar Life Sciences and AN2 Therapeutics. Earlier in his career at Anacor Pharmaceuticals, he played a pivotal role in drug substance development, contributing to the approval and commercial success of Kerydin® and Eucrisa®, topical treatments for fungal infections and eczema, respectively.

“I am pleased to welcome Kieron to Aligos. With decades of experience, Kieron’s extensive knowledge and broad expertise will undoubtedly provide invaluable leadership and oversight on all CMC-related matters,” said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. 

Dr. Wesson holds a Bachelor of Arts in Natural Sciences and a PhD in Organic Chemistry from the University of Cambridge. His appointment marks a strategic addition to Aligos' leadership team as the company continues its mission to deliver innovative therapies for patients affected by liver and viral diseases.